Skip to main content
Fig. 4 | Orphanet Journal of Rare Diseases

Fig. 4

From: Increased phototoxic burn tolerance time and quality of life in patients with erythropoietic protoporphyria treated with afamelanotide – a three years observational study

Fig. 4

Maximum pain severity (VAS) before treatment and under continuous treatment in 2018 (i.e. without involuntary treatment interruptions). The lines represent the maximal VAS of individual patients. Only values, when the time interval since the last dose did not exceed 80 days, were considered. Median pain severity before treatment VAS 10, in 2018 under treatment median VAS 4 (IQR 2–6)

Back to article page

Orphanet Journal of Rare Diseases

ISSN: 1750-1172